Business
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C
MUNICH, Germany, August 30, 2025--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.i ii
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/2acae3fb20484a61e103579dd86ff8f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XiMXZwbFdPBQC0ahsz8eGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2acae3fb20484a61e103579dd86ff8f0","width":480,"height":474}},"lazy":false},{"type":"text","content":"MUNICH, Germany, August 30, 2025--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.i ii","length":315,"tagName":"p"},{"type":"text","content":""As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination with different doses of a statin, will make it easier for physicians to tailor treatment to the individual needs of each patient", says Dr. Stefan Seyfried, Vice President, and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. "This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’".","length":475,"tagName":"p"},{"type":"text","content":"Daiichi Sankyo is prioritising the development programme further to ongoing data readouts from their funded MILOS and SANTORINI registries which continue to emphasise the persistent gaps in LDL-C management and the health inequalities this exacerbates.","length":252,"tagName":"p"},{"type":"text","content":"Professor of Public Health and Honorary Cardiologist at Imperial College London, Professor Kausik Ray added, "Heart disease remains the leading cause of death in Europe despite the significant strides forward we have taken in recent years; improvements in part enabled by more effective cholesterol management. However, data from the MILOS and SANTORINI registries exposes the ongoing inconsistencies in LDL-C management, in particular the disparities with worse LDL-C control and lower uses of evidence based therapies in women. I welcome further research that continues to explore ways that we can close these gaps and improve outcomes."","le...